Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 39,500 shares, a growth of 9.7% from the June 30th total of 36,000 shares. Based on an average trading volume of 9,100 shares, the short-interest ratio is currently 4.3 days. Approximately 1.7% of the company’s shares are short sold.
An institutional investor recently raised its position in Entasis Therapeutics stock. BlackRock Inc. raised its stake in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 29.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,657 shares of the company’s stock after purchasing an additional 3,784 shares during the quarter. BlackRock Inc. owned about 0.13% of Entasis Therapeutics worth $108,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.04% of the company’s stock.
Several analysts have commented on the stock. Zacks Investment Research cut shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 20th. ValuEngine raised shares of Entasis Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Entasis Therapeutics presently has an average rating of “Buy” and a consensus target price of $16.50.
Shares of ETTX traded up $0.05 during mid-day trading on Wednesday, reaching $7.25. The company had a trading volume of 8,000 shares, compared to its average volume of 10,942. The firm has a market capitalization of $97.83 million and a PE ratio of -0.59. The company’s fifty day simple moving average is $6.46. Entasis Therapeutics has a fifty-two week low of $3.97 and a fifty-two week high of $13.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.79 and a current ratio of 8.79.
Entasis Therapeutics (NASDAQ:ETTX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.44). On average, equities research analysts expect that Entasis Therapeutics will post -3.39 EPS for the current fiscal year.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Story: What is a good rate of return for a mutual fund?
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.